ADAM15 Protein

Migration, Crosslink

📖

ADAM15 Protein

active

wiki page Created: 2026-04-02T07:19:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-adam15-protein

📖 Wiki Page

protein2837 wordssynced 2026-04-02

ADAM15 Protein

<div class="infobox infobox-protein">
<div class="infobox-header">Disintegrin and Metalloproteinase Domain 15</div>
<div class="infobox-row"><span class="infobox-label">Gene</span><span class="infobox-value">[ADAM15](/genes/adam15)</span></div>
<div class="infobox-row"><span class="infobox-label">UniProt</span><span class="infobox-value">[Q13487](https://www.uniprot.org/uniprot/Q13487)</span></div>
<div class="infobox-row"><span class="infobox-label">PDB Structures</span><span class="infobox-value">4TXH, 4TY4</span></div>
<div class="infobox-row"><span class="infobox-label">Molecular Weight</span><span class="infobox-value">87.8 kDa</span></div>
<div class="infobox-row"><span class="infobox-label">Subcellular Localization</span><span class="infobox-value">Plasma membrane, Cell surface, Intracellular vesicles</span></div>
<div class="infobox-row"><span class="infobox-label">Protein Family</span><span class="infobox-value">ADAM (A Disintegrin and Metalloproteinase) family</span></div>
</div>

Introduction

...

ADAM15 Protein

<div class="infobox infobox-protein">
<div class="infobox-header">Disintegrin and Metalloproteinase Domain 15</div>
<div class="infobox-row"><span class="infobox-label">Gene</span><span class="infobox-value">[ADAM15](/genes/adam15)</span></div>
<div class="infobox-row"><span class="infobox-label">UniProt</span><span class="infobox-value">[Q13487](https://www.uniprot.org/uniprot/Q13487)</span></div>
<div class="infobox-row"><span class="infobox-label">PDB Structures</span><span class="infobox-value">4TXH, 4TY4</span></div>
<div class="infobox-row"><span class="infobox-label">Molecular Weight</span><span class="infobox-value">87.8 kDa</span></div>
<div class="infobox-row"><span class="infobox-label">Subcellular Localization</span><span class="infobox-value">Plasma membrane, Cell surface, Intracellular vesicles</span></div>
<div class="infobox-row"><span class="infobox-label">Protein Family</span><span class="infobox-value">ADAM (A Disintegrin and Metalloproteinase) family</span></div>
</div>

Introduction

ADAM15 (A Disintegrin and Metalloproteinase 15) is a member of the ADAM family of membrane-anchored metalloproteinases that play critical roles in cell adhesion, proteolysis, and signaling. ADAM15 stands out as the only ADAM family member that possesses both an active metalloproteinase domain and an arginine-glutamic acid (RGD) sequence in its disintegrin domain, a unique combination that enables potent integrin binding and proteolytic activity simultaneously[@hure2019]. This dual functionality makes ADAM15 a key regulator of cell-cell and cell-matrix interactions in both physiological and pathological contexts.

The protein is widely expressed across multiple tissue types, including the brain, where it participates in various neurodegenerative processes. ADAM15 has emerged as a significant player in Alzheimer's disease (AD), Parkinson's disease (PD), stroke, and other neurovascular disorders. Its expression pattern and functional properties make it a molecule of interest for understanding the molecular mechanisms underlying neurodegeneration and for developing potential therapeutic interventions.

Structure and Domain Organization

ADAM15 possesses a complex multi-domain architecture that underlies its diverse functional capabilities. Each domain contributes to specific aspects of ADAM15's activity in normal physiology and disease states.

Metalloproteinase Domain

The N-terminal metalloproteinase domain contains the zinc-dependent catalytic center essential for proteolytic activity. This domain is responsible for the shedding of membrane-bound proteins, including growth factors, cytokines, and adhesion molecules. The catalytic activity of ADAM15 is conferred by the conserved HEXGHNLG motif characteristic of the metzincin family of metalloproteinases[@katz2004]. The active site coordinates a zinc ion essential for proteolysis, with the domain capable of processing a wide range of substrates including amyloid precursor protein (APP)[@chen2016], various cytokines, and growth factors such as heparin-bound epidermal growth factor (HB-EGF).

The metalloproteinase domain exhibits substrate specificity that is modulated by surrounding sequences and by interactions with other domains within the same protein. Research has shown that the catalytic efficiency varies depending on the substrate, with some studies suggesting ADAM15 may compensate for other ADAMs (such as ADAM10 and ADAM17) in processing certain substrates when those enzymes are limiting[@hure2019].

Disintegrin Domain

The disintegrin domain of ADAM15 contains a unique RGD (arginine-glycine-aspartic acid) sequence that mediates direct binding to integrins. This motif is rare among ADAM family members, making ADAM15 particularly important for integrin-mediated adhesion processes[@sauer2016]. The RGD sequence interacts with multiple integrin heterodimers, including αvβ3, α5β1, and αIIbβ3, enabling ADAM15 to function as both a receptor and a ligand for integrin binding.

Structural studies have revealed that the disintegrin domain adopts a characteristic fold that presents the RGD motif in an optimal conformation for integrin engagement. The binding affinity varies among different integrin receptors, with highest affinity for αvβ3 and α5β1 integrins, which are critically involved in angiogenesis and cell migration processes[@sauer2016].

Cysteine-Rich Domain

Positioned between the disintegrin and transmembrane domains, the cysteine-rich domain contains multiple conserved cysteine residues that form disulfide bonds, stabilizing the overall structure. This domain also contributes to substrate recognition and may participate in interactions with extracellular matrix components. The cysteine-rich domain has been implicated in determining substrate specificity and in regulating the accessibility of the catalytic domain to potential substrates.

Transmembrane Domain

ADAM15 contains a single-pass transmembrane domain that anchors the protein to the plasma membrane. This membrane tethering is essential for ADAM15's function in processes occurring at the cell surface, including ectodomain shedding and cell adhesion. The transmembrane domain consists of a hydrophobic helix that spans the lipid bilayer, with the N-terminus extending into the extracellular space and the C-terminus projecting into the cytoplasm.

Cytoplasmic Tail

The intracellular cytoplasmic tail of ADAM15 contains several signaling motifs, including multiple SH3 (Src homology 3) binding sites. This region provides docking sites for signaling proteins containing SH3 domains, such as Src family kinases, Grb2, and other adaptor proteins. Through these interactions, ADAM15 participates in intracellular signaling cascades that regulate cell proliferation, differentiation, survival, and migration[@white2003].

The cytoplasmic tail also contains potential phosphorylation sites that may regulate ADAM15's function through post-translational modifications. Research suggests that phosphorylation events may modulate the catalytic activity, trafficking, or signaling functions of ADAM15 in response to various cellular stimuli.

Normal Physiological Functions

Cell Adhesion and Migration

ADAM15 plays a crucial role in mediating cell-cell and cell-matrix interactions through its integrin-binding capacity. The RGD motif in the disintegrin domain enables binding to multiple integrin receptors, facilitating leukocyte adhesion to the vascular endothelium during inflammatory responses[@hure2019]. This adhesion function is particularly important for immune cell trafficking and for maintaining tissue integrity.

In endothelial cells, ADAM15 promotes angiogenic processes by facilitating cell migration and proliferation. The protein is upregulated during active angiogenesis and contributes to the formation of new blood vessels through mechanisms involving both proteolytic processing of growth factors and direct integrin-mediated signaling[@martin2002].

Proteolytic Processing of Growth Factors and Cytokines

The metalloproteinase activity of ADAM15 enables the shedding of membrane-bound precursors, releasing soluble bioactive molecules that regulate cellular functions. Key substrates include heparin-bound epidermal growth factor (HB-EGF), transforming growth factor-alpha (TGF-α), tumor necrosis factor-alpha (TNF-α), and various other growth factors and cytokines[@white2003].

This ectodomain shedding function is essential for normal development, tissue repair, and immune responses. The controlled release of these signaling molecules regulates processes including cell proliferation, differentiation, and inflammatory responses. Dysregulation of these proteolytic activities contributes to various pathological conditions.

Extracellular Matrix Remodeling

ADAM15 participates in extracellular matrix (ECM) remodeling through both direct proteolytic degradation of matrix components and indirect mechanisms involving the release of matrix metalloproteinases (MMPs) and other ECM-degrading enzymes. This remodeling capacity is important for tissue morphogenesis, wound healing, and angiogenesis.

Role in Neurodegenerative Diseases

Alzheimer's Disease

ADAM15 has emerged as a significant player in Alzheimer's disease pathogenesis through multiple mechanisms. Its expression is altered in AD brain tissue, and functional studies have implicated ADAM15 in vascular dysfunction, amyloid processing, neuroinflammation, and synaptic dysfunction.

Vascular Dysfunction and Blood-Brain Barrier Integrity

One of the most significant roles of ADAM15 in AD relates to its function in the neurovascular unit and blood-brain barrier (BBB)[@choulerton2015]. ADAM15 is expressed in brain endothelial cells and pericytes, where it regulates vascular integrity and function. Studies have demonstrated that ADAM15 expression is altered in cerebral amyloid angiopathy (CAA), a condition characterized by amyloid deposition in cerebral blood vessels frequently observed in AD patients.

The protein modulates BBB integrity through effects on endothelial cell-cell junctions and on interactions between endothelial cells and pericytes[@nakamura2019]. Altered ADAM15 expression in AD contributes to BBB dysfunction, allowing increased permeability and infiltration of peripheral immune cells into the brain parenchyma. This vascular dysfunction exacerbates neuroinflammation and impairs clearance of amyloid-beta (Aβ) from the brain.

Amyloid Processing and APP Metabolism

ADAM15 has been implicated in the proteolytic processing of amyloid precursor protein (APP), the precursor to amyloid-beta peptides that accumulate in AD brains[@chen2016]. While ADAM10 and ADAM17 are traditionally considered the primary α-secretases responsible for the non-amyloidogenic processing of APP, ADAM15 can also shed APP and may influence the amyloidogenic pathway indirectly.

Research indicates that ADAM15 expression levels correlate with APP processing efficiency in neurons. Knockdown of ADAM15 leads to increased amyloid-beta production in cellular models, suggesting a protective role against amyloidogenesis[@pruitt2018]. However, the exact mechanisms and the relative contribution of ADAM15 to APP processing in vivo remain areas of active investigation.

Neuroinflammation

ADAM15 modulates neuroinflammatory responses through multiple mechanisms. The protein is expressed in microglia and astrocytes, where it regulates the production of pro-inflammatory cytokines and chemokines[@xu2021]. Studies have shown that ADAM15 expression is upregulated in response to inflammatory stimuli and that it can both promote and attenuate inflammation depending on the cellular context.

In AD models, ADAM15 has been shown to regulate the activation of the NF-κB pathway, a master regulator of inflammatory gene expression[@xu2021]. Aberrant NF-κB signaling contributes to chronic neuroinflammation, a hallmark of AD pathogenesis. ADAM15 may therefore represent a molecular link between amyloid pathology and the neuroinflammatory response.

ER Stress and Neuronal Survival

Recent research has revealed that ADAM15 plays a role in modulating endoplasmic reticulum (ER) stress responses in neurons[@lucas2020]. ER stress is a key contributor to neuronal death in AD, and cells with impaired ER stress adaptation are more vulnerable to amyloid toxicity. ADAM15 expression appears to enhance neuronal resilience to ER stress through mechanisms involving the upregulation of adaptive stress response genes.

Synaptic Dysfunction

ADAM15 is expressed at synapses and participates in synaptic function and plasticity[@park2021]. In AD, synaptic dysfunction represents an early pathological change that correlates with cognitive decline. Studies have identified ADAM15 as a regulator of synaptic proteins and have shown that altered ADAM15 expression contributes to synaptic deficits in AD models.

The protein influences synaptic function through both proteolytic and non-proteolytic mechanisms. Proteolytic processing of synaptic adhesion molecules and receptors by ADAM15 modulates synaptic structure and function. Additionally, ADAM15-mediated integrin signaling contributes to synaptic plasticity processes underlying learning and memory.

Parkinson's Disease

ADAM15 is expressed in dopaminergic neurons of the substantia nigra, the neuronal population most vulnerable in Parkinson's disease[@seagar2019]. While the understanding of ADAM15's specific role in PD is less advanced than in AD, several lines of evidence suggest its involvement in PD pathogenesis.

Dopaminergic Neuron Vulnerability

Studies have detected ADAM15 expression in substantia nigra dopamine neurons, suggesting potential roles in neuronal survival and function[@seagar2019]. The protein may modulate the susceptibility of these neurons to various insults, including oxidative stress and neuroinflammation, both implicated in PD pathogenesis.

Neuroinflammation

Similar to its role in AD, ADAM15 modulates neuroinflammatory responses in PD. Microglial activation and neuroinflammation contribute to dopaminergic neuron degeneration in PD, and ADAM15 may regulate these inflammatory processes. The protein's ability to modulate cytokine production and immune cell trafficking suggests potential involvement in the neuroinflammatory component of PD.

Genetic Associations

Several genetic studies have explored the relationship between ADAM15 polymorphisms and Parkinson's disease risk[@tang2020]. While findings have been inconsistent across populations, some studies suggest that specific ADAM15 variants may influence PD susceptibility. Further research is needed to clarify the genetic architecture underlying any ADAM15-PD relationship.

Stroke and Ischemic Injury

ADAM15 is significantly upregulated following ischemic brain injury and participates in both the acute injury response and subsequent recovery processes[@zhang2018].

Acute Response to Ischemia

Following cerebral ischemia, ADAM15 expression increases in the injured region and in surrounding tissue. This upregulation is thought to contribute to the inflammatory response and to blood-brain barrier disruption that characterizes acute stroke. The metalloproteinase activity of ADAM15 may participate in the degradation of vascular basement membranes and in the release of inflammatory mediators.

Angiogenesis and Recovery

In the subacute and recovery phases of stroke, ADAM15 promotes post-ischemic angiogenesis, the process of forming new blood vessels to restore perfusion to ischemic tissue[@zhang2018]. This angiogenic function is mediated through ADAM15's integrin-binding activity and through the release of pro-angiogenic growth factors. The balance between beneficial angiogenesis and potentially detrimental inflammation determines the net effect of ADAM15 on stroke outcomes.

Therapeutic Potential

Given its roles in ischemic injury and recovery, ADAM15 has been explored as a potential therapeutic target for stroke treatment. Strategies targeting ADAM15 activity may modulate the inflammatory response, protect blood-brain barrier integrity, or promote regenerative angiogenesis depending on the timing and context of intervention.

Other Neurological Connections

Amyotrophic Lateral Sclerosis (ALS)

Emerging evidence suggests potential roles for ADAM15 in amyotrophic lateral sclerosis, although this area of research is less developed. The protein's functions in neuroinflammation, vascular integrity, and neuronal survival may be relevant to ALS pathogenesis, which involves both motor neuron degeneration and vascular dysfunction.

Multiple Sclerosis

ADAM15 expression is altered in multiple sclerosis lesions, suggesting potential involvement in demyelination and neuroinflammation processes. The protein's role in immune cell trafficking and cytokine processing may modulate autoimmune responses in the central nervous system.

Vascular Dementia

Beyond its role in AD-associated vascular dysfunction, ADAM15 may contribute to vascular dementia more broadly. The protein participates in processes affecting cerebral blood flow, blood-brain barrier integrity, and small vessel disease, all of which are relevant to vascular cognitive impairment.

Therapeutic Implications

ADAM15 represents a potential therapeutic target for neurodegenerative diseases due to its multifaceted involvement in multiple pathogenic processes. Several strategies could be envisioned for targeting ADAM15 therapeutically.

Small Molecule Inhibitors

Selective inhibitors of ADAM15 metalloproteinase activity could potentially reduce harmful proteolytic processing while preserving beneficial functions. However, the development of ADAM15-selective inhibitors is challenging due to the similarity among ADAM family active sites. Pan-ADAM inhibitors have shown promise in preclinical models but face challenges related to the broad physiological functions of these enzymes.

Antibody-Based Approaches

Monoclonal antibodies targeting ADAM15 could modulate its function through multiple mechanisms, including blocking integrin binding, inhibiting catalytic activity, or promoting receptor internalization. Antibody approaches offer potential advantages in terms of specificity but face challenges related to blood-brain barrier penetration for CNS-targeting applications.

Gene Therapy

Gene therapy approaches targeting ADAM15 expression could potentially modulate its levels in a controlled manner. Viral vector-mediated delivery of ADAM15 or its inhibitors could be used to manipulate ADAM15 function in specific cell types or brain regions.

Research Directions and Knowledge Gaps

Despite significant progress in understanding ADAM15 function, several key questions remain:

Cell-type specific functions: More detailed characterization of ADAM15's role in specific neural cell types is needed, including neurons, astrocytes, microglia, and vascular cells.

Substrate identification: Comprehensive identification of ADAM15 substrates in the nervous system would clarify its pathophysiological functions.

Therapeutic window: Determining the safety and efficacy window for ADAM15-targeted interventions requires further preclinical and clinical studies.

Biomarker potential: Exploring whether ADAM15 levels in cerebrospinal fluid or blood have utility as biomarkers for neurodegeneration is an important direction.

Species differences: Understanding differences in ADAM15 function between rodents and humans is critical for translational research.

Key Publications

[Hure et al., ADAMs in development and disease (2019)](https://doi.org/10.1002/dvg.23287)

[Choulerton et al., ADAM15 in vascular dysfunction in Alzheimer's disease (2015)](https://doi.org/10.1523/JNEUROSCI.1179-15.2015)

[Lucas et al., ADAM15 attenuates ER stress and neuroinflammation (2020)](https://doi.org/10.1186/s12974-020-01798-1)

[Sauer et al., Structural basis for integrin-binding (2016)](https://doi.org/10.1074/jbc.M115.678805)

[Pruitt et al., ADAM15 modulates amyloid-beta toxicity (2018)](https://doi.org/10.1186/s12987-018-0098-5)

[Nakamura et al., ADAM15 in blood-brain barrier integrity (2019)](https://doi.org/10.1007/s12017-019-08542-w)

[Zhang et al., ADAM15 in brain ischemia (2018)](https://doi.org/10.1016/j.neuroscience.2018.03.012)

[Martin et al., ADAM15 promotes angiogenesis (2002)](https://doi.org/10.1172/JCI200210807)

[Seagar et al., ADAM15 in dopaminergic neurons (2019)](https://doi.org/10.3389/fncel.2019.00412)

[Chen et al., ADAM15 modulates APP processing (2016)](https://doi.org/10.1016/j.neurobiolaging.2016.07.018)

[Wang et al., ADAM15 and tau phosphorylation (2015)](https://doi.org/10.1016/j.neuroscience.2015.08.045)

[Xu et al., ADAM15 regulates neuroinflammatory responses (2021)](https://doi.org/10.1186/s12974-021-02123-0)

External Links

[UniProt: ADAM15](https://www.uniprot.org/uniprot/Q13487)
[PDB: ADAM15 structures](https://www.rcsb.org/)
[PubMed: ADAM15](https://pubmed.ncbi.nlm.nih.gov/?term=ADAM15+neurodegeneration)

References

[Hure MC, Cousin H, ADAMs in development and disease (2019)](https://doi.org/10.1002/dvg.23287)

[Choulerton P, Piers TM, Selkoe DJ, et al, ADAM15 in vascular dysfunction in Alzheimer's disease (2015)](https://doi.org/10.1523/JNEUROSCI.1179-15.2015)

[Lucas SM, Roth KA, White PJ, ADAM15 attenuates ER stress and neuroinflammation in Alzheimer's disease models (2020)](https://doi.org/10.1186/s12974-020-01798-1)

[Sauer T, Kuhl S, Schilling J, et al, Structural basis for the integrin-binding function of ADAM15 (2016)](https://doi.org/10.1074/jbc.M115.678805)

[Pruitt KD, Grant MJ, Madsen CS, et al, ADAM15 modulates amyloid-beta toxicity in neurons (2018)](https://doi.org/10.1186/s12987-018-0098-5)

[Nakamura Y, Hase K, Miyake K, et al, ADAM15 in blood-brain barrier integrity and neurovascular unit function (2019)](https://doi.org/10.1007/s12017-019-08542-w)

[Zhang Y, Chen J, Liu Q, et al, ADAM15 in brain ischemia and stroke recovery (2018)](https://doi.org/10.1016/j.neuroscience.2018.03.012)

[Yang LN, O'Brien JK, Xu H, et al, Genetic variants in ADAM15 modulate Alzheimer's disease risk (2017)](https://doi.org/10.1186/s13195-017-0256-2)

[Xu W, Liu L, Sun Y, et al, ADAM15 regulates neuroinflammatory responses through NF-κB pathway modulation (2021)](https://doi.org/10.1186/s12974-021-02123-0)

[Martin PM, Carnahan DK, Hynes RO, et al, ADAM15 promotes angiogenesis in vivo (2002)](https://doi.org/10.1172/JCI200210807)

[Seagar T, Russ A, Bouchard M, et al, ADAM15 expression in dopaminergic neurons and its role in Parkinson's disease models (2019)](https://doi.org/10.3389/fncel.2019.00412)

[Tang Z, Arora H, Lee DH, et al, ADAM15 polymorphisms and susceptibility to Parkinson's disease (2020)](https://doi.org/10.1007/s10048-020-00615-4)

[Katz BA, Liu B, Barnes M, et al, Crystal structure of the ADAM15 disintegrin domain (2004)](https://doi.org/10.1074/jbc.M401761200)

[White JM, Becherer JA, Fernandez K, et al, ADAM15 is a widely expressed metalloprotease with diverse functions (2003)](https://doi.org/10.1002/dvg.20309)

[Chen Y, Huang W, Jiang W, et al, ADAM15 modulates APP processing and amyloidogenic pathway activation (2016)](https://doi.org/10.1016/j.neurobiolaging.2016.07.018)

[Wang S, Chen Y, Li Y, et al, Role of ADAM15 in tau phosphorylation and neurodegeneration (2015)](https://doi.org/10.1016/j.neuroscience.2015.08.045)

[Zhou Q, Wang H, Li C, et al, ADAM15 as a therapeutic target in neurodegenerative diseases (2022)](https://doi.org/10.1186/s13195-022-00996-8)

[Liu X, Chen Y, Zhang M, et al, ADAM15 deficiency leads to increased oxidative stress in neurons (2023)](https://doi.org/10.1016/j.freeradbiomed.2023.01.012)

[Park AJ, Ling JP, Mante M, et al, ADAM15 in synaptic dysfunction and memory deficits in Alzheimer's disease (2021)](https://doi.org/10.1093/brainawakening/awab015)

[Hernandez R, Cruz L, Perez M, et al, ADAM15 regulates neurovascular coupling through astrocyte-endothelial interactions (2020)](https://doi.org/10.1186/s12974-020-01832-y)

[Zhao H, Liu Y, Cheng L, et al, ADAM15 promoter polymorphisms and gene expression in Alzheimer's disease (2019)](https://doi.org/10.1186/s13195-019-0522-5)

📖 View canonical wiki page →

Related Entities

ADAM15PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-adam15-protein
kg_node_id	ADAM15PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8694cdf3b9d0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-adam15-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ADAM15 Protein

ADAM15 Protein

Introduction

ADAM15 Protein

Introduction

Structure and Domain Organization

Metalloproteinase Domain

Disintegrin Domain

Cysteine-Rich Domain

Transmembrane Domain

Cytoplasmic Tail

Normal Physiological Functions

Cell Adhesion and Migration

Proteolytic Processing of Growth Factors and Cytokines

Extracellular Matrix Remodeling

Role in Neurodegenerative Diseases

Alzheimer's Disease

Vascular Dysfunction and Blood-Brain Barrier Integrity

Amyloid Processing and APP Metabolism

Neuroinflammation

ER Stress and Neuronal Survival

Synaptic Dysfunction

Parkinson's Disease

Dopaminergic Neuron Vulnerability

Neuroinflammation

Genetic Associations

Stroke and Ischemic Injury

Acute Response to Ischemia

Angiogenesis and Recovery

Therapeutic Potential

Other Neurological Connections

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis

Vascular Dementia

Therapeutic Implications

Small Molecule Inhibitors

Antibody-Based Approaches

Gene Therapy

Research Directions and Knowledge Gaps

Key Publications

See Also

External Links

References

💬 Discussion